ExpressPoints: Applying Current Evidence to Improve Outcomes for Patients With Myeloproliferative Neoplasms

Download this short summary slideset of key takeaway points on how experts approach the management of patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.
Prithviraj Bose, MD
Stephen Oh, MD, PhD
Brady L. Stein, MD, MHS
Format: Microsoft PowerPoint (.ppt)
File Size: 1.77 MB
Released: March 2, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Geron Corporation
Incyte Corporation
Sumitomo Dainippon Pharma Oncology, Inc.

Related Content

Webcast from a live expert roundtable on practice-changing guideline updates for AML, from Clinical Care Options (CCO)

Claudio Cerchione, MD, PhD
Program Director
Naval G. Daver, MD Adolfo de la Fuente Burguera, MD Courtney DiNardo, MD, MSCE person default Giovanni Martinelli, MD
Released: November 30, 2022

Downloadable PDF resource as a helpful guide for the differences between covalent and emerging non-covalent BTK inhibitors in MCL, from Clinical Care Options (CCO)

Released: November 29, 2022

On-demand webcast from a CAP satellite symposium on the role of pathology in myelodysplastic syndromes, from Clinical Care Options (CCO)

Tal Oren, MD, PhD Alexa J. Siddon, MD Cecilia Yeung, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit ABIM MOC: maximum of 1.0 Medical Knowledge MOC point ABPath MOC: maximum of 1.0 Lifelong Learning point Released: November 29, 2022 Expired: November 28, 2023

Comentários de especialistas sobre dados da Reunião Anual da SOHO 2022 sobre os inibidores de BTK para LLC e LCM, do Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings